OPKO Health Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 OPKO Health Inc 公司

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

OPKO Health Inc簡介



公司代碼OPK

公司名稱OPKO Health Inc

上市日期Nov 02, 1995

CEOCruz (Tony F)

員工數量2997

證券類型Ordinary Share

年結日Nov 02

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

國家- -

郵編- -

電話- -

網址- -

公司代碼OPK

上市日期Nov 02, 1995

CEOCruz (Tony F)

OPKO Health Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Adam E. Logal

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer

179.16K

-437500.00%

Dr. Richard M. Krasno, Ph.D.

Independent Director

103.33K

--

Dr. Elias A. Zerhouni, M.D.

President, Vice Chairman of the Board

89.60K

-500000.00%

Dr. Alice Lin-Tsing Yu, M.D., Ph.D.

Independent Director

66.49K

--

Mr. John A. Paganelli

Independent Director

--

Dr. Phillip Frost ,M.D.

Chairman of the Board, Chief Executive Officer

--

Dr. Jane H. Hsiao, Ph.D.

Vice Chairman of the Board, Chief Technical Officer

--

Mr. Steven D. (Steve) Rubin, Esq., J.D.

Executive Vice President - Administration, Director

--

Mr. Richard C. (Rick) Pfenniger, Jr.

Independent Director

--

Dr. Charles W. Bishop, Ph.D.

Chief Executive Officer of OPKO Renal

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Adam E. Logal

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer

179.16K

-437500.00%

Dr. Richard M. Krasno, Ph.D.

Independent Director

103.33K

--

Dr. Elias A. Zerhouni, M.D.

President, Vice Chairman of the Board

89.60K

-500000.00%

Dr. Alice Lin-Tsing Yu, M.D., Ph.D.

Independent Director

66.49K

--

Mr. John A. Paganelli

Independent Director

--

Dr. Phillip Frost ,M.D.

Chairman of the Board, Chief Executive Officer

--

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Health Insurers

53.91M

56.61%

Client Payers

23.51M

24.68%

Government Payers

15.60M

16.38%

Patients

2.22M

2.33%

地區USD

名稱

營收

佔比

United States

110.92M

73.13%

Chile

14.36M

15.08%

Ireland

12.08M

12.68%

Mexico

6.74M

7.07%

Spain

6.34M

6.65%

其他

-55.19M

-14.62%

業務

地區

業務USD

名稱

營收

佔比

Health Insurers

53.91M

56.61%

Client Payers

23.51M

24.68%

Government Payers

15.60M

16.38%

Patients

2.22M

2.33%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Frost Gamma Investments Trust

28.98%

Rubric Capital Management LP

6.23%

Holbrook (Bruce C)

5.26%

Hsiao (Jane H)

4.32%

The Vanguard Group, Inc.

4.21%

其他

51.01%

持股股東

佔比

Frost Gamma Investments Trust

28.98%

Rubric Capital Management LP

6.23%

Holbrook (Bruce C)

5.26%

Hsiao (Jane H)

4.32%

The Vanguard Group, Inc.

4.21%

其他

51.01%

股東類型

持股股東

佔比

Corporation

38.14%

Investment Advisor

11.81%

Individual Investor

10.57%

Hedge Fund

7.45%

Investment Advisor/Hedge Fund

5.47%

Research Firm

0.48%

Bank and Trust

0.21%

Pension Fund

0.14%

Family Office

0.05%

其他

25.69%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

453

195.81M

25.51%

-55.48M

2025Q3

457

208.31M

27.13%

-63.18M

2025Q2

472

618.23M

77.88%

-578.48K

2025Q1

498

645.32M

88.41%

+25.74M

2024Q4

501

573.04M

84.80%

-7.63M

2024Q3

497

562.18M

81.01%

-12.00M

2024Q2

501

553.77M

79.70%

+8.59M

2024Q1

492

531.83M

76.52%

-21.84M

2023Q4

493

533.01M

69.65%

+31.42M

2023Q3

496

529.79M

69.24%

+23.70M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Frost Gamma Investments Trust

222.46M

28.98%

+2.15M

+0.98%

Nov 21, 2025

Rubric Capital Management LP

47.79M

6.23%

--

Sep 30, 2025

Holbrook (Bruce C)

40.38M

5.26%

--

Feb 24, 2025

Hsiao (Jane H)

33.13M

4.32%

--

Apr 02, 2025

The Vanguard Group, Inc.

37.45M

4.88%

-702.82K

-1.84%

Sep 30, 2025

Frost Group, L.L.C.

30.13M

3.92%

--

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

29.68M

3.87%

+1.46M

+5.19%

Sep 30, 2025

GJN 2021 Trust

19.91M

2.59%

--

Feb 24, 2025

EGN 2021 Trust

19.91M

2.59%

--

Feb 24, 2025

Geode Capital Management, L.L.C.

10.99M

1.43%

+568.87K

+5.46%

Sep 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.53%

State Street SPDR S&P Health Care Services ETF

0.46%

VanEck Israel ETF

0.14%

Humankind US Stock ETF

0.1%

iShares U.S. Healthcare Providers ETF

0.1%

Goldman Sachs Innovate Equity ETF

0.06%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.05%

iShares Russell 2000 Value ETF

0.04%

iShares Biotechnology ETF

0.04%

Invesco RAFI US 1500 Small-Mid ETF

0.04%

Invesco NASDAQ Future Gen 200 ETF

佔比0.53%

State Street SPDR S&P Health Care Services ETF

佔比0.46%

VanEck Israel ETF

佔比0.14%

Humankind US Stock ETF

佔比0.1%

iShares U.S. Healthcare Providers ETF

佔比0.1%

Goldman Sachs Innovate Equity ETF

佔比0.06%

iShares MSCI USA Small-Cap Min Vol Factor ETF

佔比0.05%

iShares Russell 2000 Value ETF

佔比0.04%

iShares Biotechnology ETF

佔比0.04%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.04%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據